These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo. Feng Z; Xu S; Liu M; Zeng YX; Kang T Cancer Lett; 2010 Nov; 297(2):190-7. PubMed ID: 20619533 [TBL] [Abstract][Full Text] [Related]
4. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model. Qamar L; Davis R; Anwar A; Behbakht K Gynecol Oncol; 2008 Sep; 110(3):425-31. PubMed ID: 18619662 [TBL] [Abstract][Full Text] [Related]
5. [Silencing of cell cycle checkpoint kinase gene enhances cisplatin-induced apoptosis of lung cancer cells]. Ye F; Xie DX; Lu YP; Gao QL Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):804-9. PubMed ID: 20137342 [TBL] [Abstract][Full Text] [Related]
6. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1. Duan L; Perez RE; Hansen M; Gitelis S; Maki CG Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935 [TBL] [Abstract][Full Text] [Related]
7. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Mack PC; Gandara DR; Lau AH; Lara PN; Edelman MJ; Gumerlock PH Cancer Chemother Pharmacol; 2003 Apr; 51(4):337-48. PubMed ID: 12721762 [TBL] [Abstract][Full Text] [Related]
8. Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation. Zhao X; Kim IK; Kallakury B; Chahine JJ; Iwama E; Pierobon M; Petricoin E; McCutcheon JN; Zhang YW; Umemura S; Chen V; Wang C; Giaccone G Mol Oncol; 2021 Apr; 15(4):1130-1145. PubMed ID: 33320980 [TBL] [Abstract][Full Text] [Related]
9. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells. Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of CHK1 kinase by Gö6976 converts 8-chloro-adenosine-induced G2/M arrest into S arrest in human myelocytic leukemia K562 cells. Jia XZ; Yang SY; Zhou J; Li SY; Ni JH; An GS; Jia HT Biochem Pharmacol; 2009 Mar; 77(5):770-80. PubMed ID: 19059218 [TBL] [Abstract][Full Text] [Related]
11. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer. Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515 [TBL] [Abstract][Full Text] [Related]
12. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Sen T; Tong P; Stewart CA; Cristea S; Valliani A; Shames DS; Redwood AB; Fan YH; Li L; Glisson BS; Minna JD; Sage J; Gibbons DL; Piwnica-Worms H; Heymach JV; Wang J; Byers LA Cancer Res; 2017 Jul; 77(14):3870-3884. PubMed ID: 28490518 [TBL] [Abstract][Full Text] [Related]
13. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells. Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest. Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202 [TBL] [Abstract][Full Text] [Related]
15. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells. Gavrilov V; Lavrenkov K; Ariad S; Shany S Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259 [TBL] [Abstract][Full Text] [Related]
16. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor. Ueda Y; Igishi T; Hashimoto K; Suyama H; Araki K; Sumikawa T; Takeda K; Nakazaki H; Matsunami K; Kodani M; Shigeoka Y; Matsumoto S; Shimizu E Int J Oncol; 2009 Mar; 34(3):689-96. PubMed ID: 19212674 [TBL] [Abstract][Full Text] [Related]
17. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts. Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935 [TBL] [Abstract][Full Text] [Related]
18. The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer. Yin M; Hapke G; Guo B; Azrak RG; Frank C; Rustum YM Oncogene; 2001 Aug; 20(38):5249-57. PubMed ID: 11536038 [TBL] [Abstract][Full Text] [Related]
19. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells. Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911 [TBL] [Abstract][Full Text] [Related]
20. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells. Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]